减低强度预处理用于噬血细胞性淋巴组织细胞增生症及原发性免疫缺陷的造血细胞移植
多中心前瞻性2期试验评估美法仑、氟达拉滨及中间时机阿仑单抗减低强度预处理用于HLA相合或单个HLA位点不合的相关或无关供者造血细胞移植,主要终点为1年总生存。34例噬血细胞性淋巴组织细胞增生症(HLH)和12例其他原发性免疫缺陷患者接受移植,中位随访20个月,1年总生存80.4%(90%CI 68.6%-88.2%),但多数存活患者需供者淋巴细胞输注或二次移植。
要点
- 1年总生存80.4%(90%CI 68.6%-88.2%),早期死亡率低。
- 1年时无需供者淋巴细胞输注或二次移植且持续植入的存活比例为39.1%(95%CI 25.2%-54.6%)。
- 2例原发植入失败,18例发生继发植入失败或需二次干预(多为供者淋巴细胞输注)。
核心结论
- 减低强度预处理虽早期死亡率低,但多数存活患者需供者淋巴细胞输注或二次造血细胞移植,未来方案需在维持低早期死亡率的同时改善持续植入。
研究设计与样本
- 多中心前瞻性2期试验,采用美法仑、氟达拉滨及中间时机阿仑单抗减低强度预处理,用于HLA相合或单个HLA位点不合的相关或无关供者造血细胞移植,以儿童为主;移植物抗宿主病预防为环孢素联合甲泼尼龙;主要终点为1年总生存;共移植34例HLH和12例其他原发性免疫缺陷患者;试验注册号NCT 01998633。
主要发现
- 中位随访20个月,移植患者1年总生存为80.4%(90%CI 68.6%-88.2%)。
- 16个月前另增5例死亡,18个月总生存概率为66.7%(90%CI 52.9%-77.3%)。
- 2例发生原发植入失败,18例发生继发植入失败或需二次干预(多为供者淋巴细胞输注)。
- 1年时存活且持续植入、无需供者淋巴细胞输注或二次移植的比例为39.1%(95%CI 25.2%-54.6%);存活且植入(伴或不伴供者淋巴细胞输注)的比例为60.9%(95%CI 45.4%-74.9%)。
- 第100天II至IV级急性移植物抗宿主病发生率为17.4%(95%CI 8.1%-29.7%),1年慢性移植物抗宿主病发生率为26.7%(95%CI 14.6%-40.4%)。
临床怎么用
- 作者认为这些结果说明需要未来在维持低早期死亡率的同时改善持续植入的方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning for disorders associated with excessive inflammation such as hemophagocytic lymphohistiocytosis (HLH) is associated with early mortality. A multicenter prospective phase 2 trial of reduced-intensity conditioning with melphalan, fludarabine, and intermediate-timing alemtuzumab was conducted for HLA matched or single HLA locus mismatched related or unrelated donor HCT in a largely pediatric cohort. Graft-versus-host disease (GVHD) prophylaxis was cyclosporine with methylprednisolone. The primary end point was 1-year overall survival (OS). Thirty-four patients with HLH and 12 with other primary immune deficiencies were transplanted. With a median follow-up of 20 months, the 1-year OS for transplanted patients was 80.4% (90% confidence interval [CI], 68.6%-88.2%). Five additional deaths by 16 months yielded an 18-month OS probability of 66.7% (90% CI, 52.9%-77.3%). Two patients experienced primary graft failure, and 18 patients either experienced a secondary graft failure or required a second intervention (mostly donor lymphocyte infusion [DLI]). At 1 year, the proportion of patients alive with sustained engraftment without DLI or second HCT was 39.1% (95% CI, 25.2%-54.6%), and that of being alive and engrafted (with or without DLI) was 60.9% (95% CI, 45.4 %-74.9%). The day 100 incidence of grade II to IV acute GVHD was 17.4% (95% CI, 8.1%-29.7%), and 1-year incidence of chronic GVHD was 26.7% (95% CI, 14.6%-40.4%). Although the trial demonstrated low early mortality, the majority of surviving patients required DLI or second HCT. These results demonstrate a need for future approaches that maintain low early mortality with improved sustained engraftment. The trial was registered at Clinical Trials.gov (NCT 01998633).
引用
- Allen CE, Marsh R, Dawson P, et al. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood. 2018. PMID: 29997222. doi:10.1182/blood-2018-01-828277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。